The company grew 7% in 3Q20 as growth in U.S. trauma sales more than offset continuing COVID-related challenges in international markets.

The company's joint replacement business grew over 9% in 3Q20 as it prepares to enter the high-growth foot and ankle joint replacement market.

Despite gaining market share in Japan, the company's sales dropped by double-digits for the third consecutive quarter due to COVID and price reductions.

More than a year after announcing its intention to acquire Wright Medical for $5.4 billion, Stryker today completed the purchase.

The company grew +8.3% in 3Q20 due to its new product cadence, contracting wins in large health systems and geographic expansion of its revenue footprint.

U.S. spinal sales drove Orthofix's sequential improvement in 3Q20 but were not enough to overcome lingering procedure volume declines due to COVID.

The company grew +2.9% in 3Q20 as it begins a new phase of its strategic transformation that includes focus on high growth business lines.

The company grew +41% in 3Q20, driven by a record-breaking September. ATEC sees itself as well-positioned to take share from both large and small players.

While the company's orthobiologics business remains impacted by COVID, gains from joint preservation and restoration products offset the losses.

The company declined -6.8% in 3Q20, as it remains impacted by the slower recovery of primary arthroplasty surgeries compared to revision and trauma.